Joana Fort

Dr. Joana Fort

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028, Barcelona, Spain.
+2
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cell
Verified
Journal Article
Closed access
María Isabel Hernández AlvarezMaría Isabel Hernández Alvarez
María Isabel Hernández Alvarez
DSDavid Sebastián
David Sebastián
SVSara Vives
Sara Vives
SISaška Ivanova
Saška Ivanova
PBPaola Bartoccioni
Paola Bartoccioni
AZAntonio Zorzano
Antonio Zorzano

1 June 2010 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
JCJuan-José Chillarón
Juan-José Chillarón
MFMariona Font-Llitjós
Mariona Font-Llitjós
Joana FortJoana Fort
Joana Fort
AZAntonio Zorzano
Antonio Zorzano
DGDavid S. Goldfarb
David S. Goldfarb
MPManuel Palacín
Manuel Palacín

1 October 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Joana FortJoana Fort
Joana Fort
LBLaura R. de la Ballina
Laura R. de la Ballina
HBHans E. Burghardt
Hans E. Burghardt
CFCarles Ferrer-Costa
Carles Ferrer-Costa
JTJavier Turnay
Javier Turnay
MPManuel Palacín
Manuel Palacín
4F2hc (CD98hc) is a multifunctional type II membrane glycoprotein involved in amino acid transport and cell fusion, adhesion, and transformation. The structure of the ectodomain of human 4F2hc has been solved using monoclinic (Protein Data Bank code 2DH2) and orthorhombic (Protein Data Bank code 2DH3) crystal forms at 2.1 and 2.8 Å, respectively. It is composed of a (βα)8 barrel and an antiparallel β8 sandwich related to bacterial α-glycosidases, although lacking key catalytic residues and consequently catalytic activity. 2DH3 is a dimer with Zn2+ coordination at the interface. Human 4F2hc expressed in several cell types resulted in cell surface and Cys109 disulfide bridge-linked homodimers with major architectural features of the crystal dimer, as demonstrated by cross-linking experiments. 4F2hc has no significant hydrophobic patches at the surface. Monomer and homodimer have a polarized charged surface. The N terminus of the solved structure, including the position of Cys109 residue located four residues apart from the transmembrane domain, is adjacent to the positive face of the ectodomain. This location of the N terminus and the Cys109-intervening disulfide bridge imposes space restrictions sufficient to support a model for electrostatic interaction of the 4F2hc ectodomain with membrane phospholipids. These results provide the first crystal structure of heteromeric amino acid transporters and suggest a dynamic interaction of the 4F2hc ectodomain with the plasma membrane.

1 April 2005 in Physiology
Verified
Journal Article
Closed access
PDF file
MPManuel Palacín
Manuel Palacín
VNVirginia Nunes
Virginia Nunes
MFMariona Font-Llitjós
Mariona Font-Llitjós
MJMaite Jiménez-Vidal
Maite Jiménez-Vidal
Joana FortJoana Fort
Joana Fort
AZAntonio Zorzano
Antonio Zorzano
Heteromeric amino acid transporters (HATs) are composed of a heavy ( SLC3 family) and a light ( SLC7 family) subunit. Mutations in system b0,+(rBAT-b0,+AT) and in system y+L (4F2hc-y+LAT1) cause the primary inherited aminoacidurias (PIAs) cystinuria and lysinuric protein intolerance, respectively. Recent developments [including the identification of the first Hartnup disorder gene (B0AT1; SLC6A19)] and knockout mouse models have begun to reveal the basis of renal and intestinal reabsorption of amino acids in mammals.

21 January 2014 in Human Mutation
Verified
Journal Article
Closed access
PDF file
AGAngels García-Cazorla
Angels García-Cazorla
AOAlfonso Oyarzábal
Alfonso Oyarzábal
Joana FortJoana Fort
Joana Fort
CRConcepción Robles
Concepción Robles
ECEsperanza Castejón
Esperanza Castejón
SASergi Beltran Agulló
Sergi Beltran Agulló
Inactivating mutations in the BCKDK gene, which codes for the kinase responsible for the negative regulation of the branched‐chain α‐keto acid dehydrogenase complex (BCKD), have recently been associated with a form of autism in three families. In this work, two novel exonic BCKDK mutations, c.520C>G/p.R174G and c.1166T>C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched‐chain amino acids (BCAAs), developmental delay, microcephaly, and neurobehavioral abnormalities. Functional analysis of the mutations confirmed the missense character of the c.1166T>C change and showed a splicing defect r.[520c>g;521_543del]/p.R174Gfs1*, for c.520C>G due to the presence of a new donor splice site. Mutation p.L389P showed total loss of kinase activity. Moreover, patient‐derived fibroblasts showed undetectable (p.R174Gfs1*) or barely detectable (p.L389P) levels of BCKDK protein and its phosphorylated substrate (phospho‐E1α), resulting in increased BCKD activity and the very rapid BCAA catabolism manifested by the patients’ clinical phenotype. Based on these results, a protein‐rich diet plus oral BCAA supplementation was implemented in the patient homozygous for p.R174Gfs1*. This treatment normalized plasma BCAA levels and improved growth, developmental and behavioral variables. Our results demonstrate that BCKDK mutations can result in neurobehavioral deficits in humans and support the rationale for dietary intervention.

18 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Ekaitz Errasti-MurugarrenEkaitz Errasti-Murugarren
Ekaitz Errasti-Murugarren
Joana FortJoana Fort
Joana Fort
PBPaola Bartoccioni
Paola Bartoccioni
LDLucía Díaz
Lucía Díaz
EPEls Pardon
Els Pardon
MPManuel Palacín
Manuel Palacín
L-amino acid transporters (LATs) play key roles in human physiology and are implicated in several human pathologies. LATs are asymmetric amino acid exchangers where the low apparent affinity cytoplasmic side controls the exchange of substrates with high apparent affinity on the extracellular side. Here, we report the crystal structures of an LAT, the bacterial alanine-serine-cysteine exchanger (BasC), in a non-occluded inward-facing conformation in both apo and substrate-bound states. We crystallized BasC in complex with a nanobody, which blocks the transporter from the intracellular side, thus unveiling the sidedness of the substrate interaction of BasC. Two conserved residues in human LATs, Tyr 236 and Lys 154, are located in equivalent positions to the Na1 and Na2 sites of sodium-dependent APC superfamily transporters. Functional studies and molecular dynamics (MD) calculations reveal that these residues are key for the asymmetric substrate interaction of BasC and in the homologous human transporter Asc-1.